Some of them have been described as predictors of therapy response or ways of helping to guide therapies such as TMPRSS2-ERG fusion, PTEN status, presence of AR-V7 splice variant, mutations in DNA-repair genes such as BRCA2/1, etc. [53] in metastatic prostate cancer patients. This evidence concerns the gene BRCA2 and metastatic prostate carcinoma.